{"id":"flu-cy-atg-or-cy-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / neutropenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Graft-versus-host disease"},{"rate":null,"effect":"Hemorrhagic cystitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a purine analog that inhibits DNA synthesis in lymphocytes; cyclophosphamide is an alkylating agent that causes DNA cross-linking and cell death; and ATG is a polyclonal antibody that depletes T cells. Together, these agents create immunosuppression and myeloablation sufficient to allow engraftment of donor stem cells while reducing graft rejection and graft-versus-host disease.","oneSentence":"A conditioning regimen combining fludarabine, cyclophosphamide, and anti-thymocyte globulin (ATG) to suppress the immune system and prepare patients for hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:34.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies and severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06069180","phase":"PHASE4","title":"The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-11-15","conditions":"Severe Aplastic Anemia","enrollment":160},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT05921318","phase":"","title":"Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-06-01","conditions":"Hematologic Malignancy, Stem Cell Transplant Complications","enrollment":20},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT01145976","phase":"PHASE3","title":"Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-03","conditions":"Aplastic Anemia","enrollment":98},{"nctId":"NCT00774527","phase":"PHASE3","title":"Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2003-03","conditions":"Bone Marrow Failure Syndromes","enrollment":82},{"nctId":"NCT00275678","phase":"PHASE3","title":"Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Blood Stem Cell Transplant","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Flu/Cy/ATG or Cy/ATG","genericName":"Flu/Cy/ATG or Cy/ATG","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A conditioning regimen combining fludarabine, cyclophosphamide, and anti-thymocyte globulin (ATG) to suppress the immune system and prepare patients for hematopoietic stem cell transplantation. Used for Conditioning prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies and severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}